MediciNova, Inc. (4875.T)
JPY 217.0
(0.0%)
JPY 217.0
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 3.89 Million USD | -0.54% |
| 2022 | 3.91 Million USD | 4.92% |
| 2021 | 3.72 Million USD | -8.88% |
| 2020 | 4.09 Million USD | 141.57% |
| 2019 | 1.69 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 2.99 Million USD | -2.12% |
| 2024 Q1 | 3.06 Million USD | -21.28% |
| 2023 Q3 | 3.46 Million USD | -2.13% |
| 2023 Q2 | 3.54 Million USD | 4.0% |
| 2023 FY | 3.89 Million USD | -0.54% |
| 2023 Q1 | 3.4 Million USD | 381.35% |
| 2023 Q4 | 3.89 Million USD | 12.24% |
| 2022 Q4 | 707.71 Thousand USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 3.24 Billion JPY | 99.88% |
| PRISM BioLab Co.,LTD | 63.41 Million JPY | 93.863% |
| GNI Group Ltd. | 26.34 Billion JPY | 99.985% |
| Linical Co., Ltd. | 10.3 Billion JPY | 99.962% |
| Trans Genic Inc. | 3.81 Billion JPY | 99.898% |
| MEDINET Co., Ltd. | 590.2 Million JPY | 99.341% |
| Soiken Holdings Inc. | 697.02 Million JPY | 99.442% |
| Cytori Cell Research Institute, Inc. | 3.02 Billion JPY | 99.871% |
| AnGes, Inc. | 2.78 Billion JPY | 99.86% |
| OncoTherapy Science, Inc. | 513.6 Million JPY | 99.242% |
| Nxera Pharma Co., Ltd. | 90.38 Billion JPY | 99.996% |
| Immuno-Biological Laboratories Co., Ltd. | 353.27 Million JPY | 98.898% |
| NanoCarrier Co., Ltd. | 1.64 Billion JPY | 99.764% |
| Carna Biosciences, Inc. | 472.35 Million JPY | 99.176% |
| CanBas Co., Ltd. | 91.98 Million JPY | 95.769% |
| D. Western Therapeutics Institute, Inc. | 1.09 Billion JPY | 99.644% |
| RaQualia Pharma Inc. | 809.83 Million JPY | 99.519% |
| Chiome Bioscience Inc. | 593.73 Million JPY | 99.345% |
| Kidswell Bio Corporation | 4.25 Billion JPY | 99.909% |
| PeptiDream Inc. | 29.11 Billion JPY | 99.987% |
| Oncolys BioPharma Inc. | 566.5 Million JPY | 99.313% |
| Ribomic Inc. | 155.8 Million JPY | 97.502% |
| SanBio Company Limited | 2.25 Billion JPY | 99.827% |
| Healios K.K. | 11.28 Billion JPY | 99.966% |
| BrightPath Biotherapeutics Co., Ltd. | 251.26 Million JPY | 98.451% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 369 Million JPY | 98.945% |
| Delta-Fly Pharma, Inc. | 241.49 Million JPY | 98.389% |
| StemRIM | 187 Million JPY | 97.919% |
| CellSource Co., Ltd. | 677.73 Million JPY | 99.426% |
| FunPep Company Limited | 189.32 Million JPY | 97.945% |
| Kringle Pharma, Inc. | 596.95 Million JPY | 99.348% |
| Stella Pharma Corporation | 1.44 Billion JPY | 99.73% |
| TMS Co., Ltd. | 97.68 Million JPY | 96.016% |
| Noile-Immune Biotech Inc. | 91.49 Million JPY | 95.747% |
| Cuorips Inc. | 200.96 Million JPY | 98.064% |
| K Pharma,Inc. | 209.13 Million JPY | 98.139% |
| Takara Bio Inc. | 11.42 Billion JPY | 99.966% |
| ReproCELL Incorporated | 741.03 Million JPY | 99.475% |
| PhoenixBio Co., Ltd. | 917.71 Million JPY | 99.576% |
| StemCell Institute Inc. | 3.85 Billion JPY | 99.899% |
| Japan Tissue Engineering Co., Ltd. | 908.43 Million JPY | 99.572% |
| CellSeed Inc. | 301.04 Million JPY | 98.707% |